AB084. Docetaxel therapy for hormone-sensitive prostate cancer—single center result

BACKGROUND: Androgen-deprivation therapy (ADT) has been the treatment for metastatic prostate cancer for more 75 years. We assessed whether concomitant treatment with ADT added to docetaxel would result in patients newly-diagnosed metastatic hormone-sensitive prostate cancer for longer overall survi...

Descripción completa

Detalles Bibliográficos
Autores principales: Shao, Qiang, Du, Yuan, Zhang, Fengbo, Tian, Ye
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2015
Materias:
Podium Lecture
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4708668/
http://dx.doi.org/10.3978/j.issn.2223-4683.2015.s084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4708668/
http://dx.doi.org/10.3978/j.issn.2223-4683.2015.s084

Ejemplares similares